Research on the expression of E-cadherin in lung cancer tumors with different histological structures
https://doi.org/10.37748/2686-9039-2024-5-4-2
EDN: UDWECG
Abstract
Purpose of the study. To conduct a comparative analysis of E-cadherin expression in inoperable patients with non-small cell lung cancer (NSCLC) cells and with different survival rates.
Materials and methods. The study included 96 patients with inoperable NSCLC: 84 (87.5 %) men and 12 (12.5 %) women, whose average age was 62.4 ± 0.68 years. Squamous cell carcinoma (SCC) was diagnosed in 78 (81.25 %) patients, and adenocarcinoma (AC) with a tumor differentiation grade of G2-G3 in 18 (18.75 %). The patients were treated and monitored at the National Medical Research Centre for Oncology. The expression of cadherins was determined in the tumor cells of the biopsy specimens. The obtained data have been processed using the Statistica 13.0 program (StatSoftInc., USA). The studied data have been checked for compliance with the normal distribution using the Shapiro-Wilk criterion.
Results. The following distribution of patients with NSCLC was noted: IIA – 2 (2.1 %), IIB – 14 (14.6 %), IIIA – 51 (53.1 %), IIIB – 29 (30.2 %), i. e. the frequency of stage III is higher than stage II (83.3 % (n = 80) versus 16.7 % (n = 16), p < 0.001). Fatal outcome occurred in the SCC group within 1 year in 28 patients, within 1 to 2 years – in 30, 20 patients survived for 3 years or more. For AC, these figures were 6,5 and 7 respectively. The analysis revealed that E-cadherin expression was noted in both squamous cell carcinoma and lung adenocarcinoma: Me 55 [LQ 37; UQ 65] and Me 50 [LQ 40; UQ 70], respectively.
Conclusions. 1. The analysis revealed that E-cadherin expression was observed in both squamous cell carcinoma and lung adenocarcinomas without statistically significant differences between the compared groups (p = 0.25). 2. Statistically significant differences in the levels of E-cadherin expression were noted in the biopsy samples of the 2 groups only with survival up to 1 year and up to 3 years or more (p < 0.05).
About the Authors
E. N. KolesnikovRussian Federation
Evgenii N. Kolesnikov – Dr. Sci. (Med.), MD, associate professor, head of the Department of Abdominal Oncology No. 1, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
ORCID: https://orcid.org/0000-0001-9749-709X, SPIN: 8434-6494, AuthorID: 347457, Scopus Author ID: 57190297598
Competing Interests:
the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article
O. N. Stateshny
Russian Federation
Oleg N. Stateshny – MD, oncologist at the Department of Thoracic Oncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
ORCID: https://orcid.org/0000-0003-4513-7548, SPIN: 9917-1975, AuthorID: 1067071
Competing Interests:
the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article
D. A. Kharagezov
Russian Federation
Dmitriy A. Kharagezov – Cand. Sci. (Med.), MD, head of the Department of Thoracic Oncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
ORCID: https://orcid.org/0000-0003-0640-2994, SPIN: 5120-0561, AuthorID: 733789, ResearcherID: AAZ-3638-2021, Scopus Author ID: 56626499300
Competing Interests:
the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article
E. A. Mirzoyan
Russian Federation
Ellada A. Mirzoyan – Cand. Sci. (Med.), MD, researcher at the Thoracic Department, oncologist at the Department of Thoracic Oncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
ORCID: https://orcid.org/0000-0002-0328-9714, SPIN: 2506-8605, AuthorID: 1002948, ResearcherID: AAZ-2780-2021, Scopus Author ID: 57221118516
Competing Interests:
the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article
T. G. Ayrapetova
Russian Federation
Tamara G. Ayrapetova – Cand. Sci. (Med.), PhD, MD, oncologist at the Department of Thoracic Oncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
ORCID: https://orcid.org/0000-0001-5287-5800, SPIN: 8121-4039, AuthorID: 794672
Competing Interests:
the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article
A. G. Milakin
Russian Federation
Anton G. Milakin – MD, oncologist at the Department of Thoracic Oncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
ORCID: https://orcid.org/0000-0002-2589-7606, SPIN: 7737-4737, AuthorID: 794734
Competing Interests:
the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article
K. D. Iozefi
Russian Federation
Kristian D. Iozefi – MD, thoracic surgeon at the Department of Thoracic Oncology, National Medical Research Centre for Oncology, Rostov-on-Don, Russian Federation
ORCID: https://orcid.org/0000-0002-5351-3251, SPIN: 1232-3097, AuthorID: 1122592, ResearcherID: AAZ-3632-2021
Competing Interests:
the authors declare that there are no obvious and potential conflicts of interest associated with the publication of this article
References
1. Kit OI, Turkin IN, Kharagezov DA, Lazutin YuN, Leiman IA, Chubaryan AV, et al. Sequential bronchoplastic upper lobectomy as a surgical component of multimodal treatment for synchronous bilateral multiple primary non-small cell lung cancer. Siberian Journal of Oncology. 2022;21(3):143−150. (In Russ.). https://doi.org/10.21294/1814-4861-2022-21-3-143-150
2. The state of cancer care for the Russian population in 2023. Edited by A. D. Kaprin, V. V. Starinsky, A. O. Shakhzadova Moscow: P. A. Herzen MNIOI – Branch of the National Medical Research Radiological Center, 2024, 262 p. (In Russ.).
3. Iozefi KD, Kharagezov DA, Lazutin YuN, Mirzoyan EA, Hayrapetova TG, Leyman IA, et al. Intraoperative pleurodesis as a way to prevent prolonged air leakage after anatomical lung resections for cancer. Modern Problems of Science and Education. (In Russ.). 2024;(1):27. https://doi.org/10.17513/spno.33286, EDN: NMZYZG
4. Price A. Emerging developments of chemoradiotherapy in stage III NSCLC. Nature Reviews Clinical Oncology. 2013;9(10): 591–598. https://doi.org/10.1038/nrclinonc.2012.135
5. Malignant neoplasm of the bronchi and lung. Clinical Recommendations. 2021, 116 p. Available at: https://oncology-association.ru/wp-content/uploads/2021/02/rak-legkogo-2021.pdf?ysclid=m3gxqlmm8k225907433, Accessed: 24.10.2024.
6. Laktionov KK, Artamonova EV, Borisova TN, Breder VV, Bychkov YuM, Vladimirova LYu, et al. Malignant neoplasm of the bronchi and lung. Modern Oncology. 2021;23(3):369–402. (In Russ.). https://doi.org/10.26442/18151434.2021.3.20104, EDN: NPNNMP
7. Faurobert E, Bouin AP, Albiges-Rizo C. Microenvironment, tumor cell plasticity, and cancer. Curr Opin Oncol. 2015 Jan;27(1):64–70. https://doi.org/10.1097/CCO.0000000000000154
8. Edwards LA, Woolard K, Son MJ, Li A, Lee J, Ene C, et al. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst. 2011 Aug 3;103(15):1162–1178. https://doi.org/10.1093/jnci/djr224
9. Hornsveld M, Tenhagen M, van de Ven RA, Smits AMM, van Triest MH, van Amersfoort M, et al. Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer. Cell Death Differ. 2016 Sep 1;23(9):1483–1492. https://doi.org/10.1038/cdd.2016.33
10. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, Beck A, et al. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod Pathol. 2004 Apr;17(4):430–439. https://doi.org/10.1038/modpathol.3800041
11. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, et al. Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer. 2010 Dec;70(3):320–328. https://doi.org/10.1016/j.lungcan.2010.02.013
12. Zhang H, Liu J, Yue D, Gao L, Wang D, Zhang H, et al. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol. 2013 Nov;66(11):937–945. https://doi.org/10.1136/jclinpath-2013-201467
13. Gkogkou P, Peponi E, Ntaskagiannis D, Murray S, Demou A, Sainis I, et al. E-Cadherin and Syndecan-1 Expression in Patients With Advanced Non-small Cell Lung Cancer Treated With Chemoradiotherapy. In Vivo. 2020;34(1):453–459. https://doi.org/10.21873/invivo.11795
14. He LY, Zhang H, Wang ZK, Zhang HZ. Diagnostic and prognostic significance of E-cadherin and Ki-67 expression in nonsmall cell lung cancer patients. Eur Rev Med Pharmacol Sci. 2016 Sep;20(18):3812–3817.
Supplementary files
Review
For citations:
Kolesnikov E.N., Stateshny O.N., Kharagezov D.A., Mirzoyan E.A., Ayrapetova T.G., Milakin A.G., Iozefi K.D. Research on the expression of E-cadherin in lung cancer tumors with different histological structures. South Russian Journal of Cancer. 2024;5(4):14-19. https://doi.org/10.37748/2686-9039-2024-5-4-2. EDN: UDWECG